These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 8765411

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells.
    Zou JP, Yamamoto N, Fujii T, Takenaka H, Kobayashi M, Herrmann SH, Wolf SF, Fujiwara H, Hamaoka T.
    Int Immunol; 1995 Jul; 7(7):1135-45. PubMed ID: 8527411
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Molecular mechanisms underlying IFN-gamma-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12.
    Yu WG, Yamamoto N, Takenaka H, Mu J, Tai XG, Zou JP, Ogawa M, Tsutsui T, Wijesuriya R, Yoshida R, Herrmann S, Fujiwara H, Hamaoka T.
    Int Immunol; 1996 Jun; 8(6):855-65. PubMed ID: 8671675
    [Abstract] [Full Text] [Related]

  • 6. Interleukin 12 gene transfer into skin distant from the tumor site elicits antimetastatic effects equivalent to local gene transfer.
    Oshikawa K, Rakhmilevich AL, Shi F, Sondel PM, Yang N, Mahvi DM.
    Hum Gene Ther; 2001 Jan 20; 12(2):149-60. PubMed ID: 11177552
    [Abstract] [Full Text] [Related]

  • 7. The anti-tumor effects of IL-12 involve enhanced IFN-gamma production by anti-tumor T cells, their accumulation to tumor sites and in situ IFN-gamma production.
    Fujiwara H, Hamaoka T.
    Leukemia; 1997 Apr 20; 11 Suppl 3():570-1. PubMed ID: 9209457
    [Abstract] [Full Text] [Related]

  • 8. IL-12-induced tumor regression correlates with in situ activity of IFN-gamma produced by tumor-infiltrating cells and its secondary induction of anti-tumor pathways.
    Yu WG, Ogawa M, Mu J, Umehara K, Tsujimura T, Fujiwara H, Hamaoka T.
    J Leukoc Biol; 1997 Oct 20; 62(4):450-7. PubMed ID: 9335314
    [Abstract] [Full Text] [Related]

  • 9. The development of peritumoral stroma required for IL-12 induced tumor regression depends on the T cell/IFN-gamma-involving host-tumor interaction.
    Uekusa Y, Ogawa M, Gao P, Iwasaki M, Ono S, Tsujimura T, Nakazawa M, Sakuda M, Clancy B, Fujiwara H, Hamaoka T.
    Int J Oncol; 2000 Apr 20; 16(4):805-14. PubMed ID: 10717251
    [Abstract] [Full Text] [Related]

  • 10. Enhanced induction of very late antigen 4/lymphocyte function-associated antigen 1-dependent T-cell migration to tumor sites following administration of interleukin 12.
    Ogawa M, Tsutsui T, Zou JP, Mu J, Wijesuriya R, Yu WG, Herrmann S, Kubo T, Fujiwara H, Hamaoka T.
    Cancer Res; 1997 Jun 01; 57(11):2216-22. PubMed ID: 9187124
    [Abstract] [Full Text] [Related]

  • 11. Differential IL-12 responsiveness of T cells but not of NK cells from tumor-bearing mice in IL-12-responsive versus -unresponsive tumor models.
    Iwasaki M, Yu WG, Uekusa Y, Nakajima C, Yang YF, Gao P, Wijesuriya R, Fujiwara H, Hamaoka T.
    Int Immunol; 2000 May 01; 12(5):701-9. PubMed ID: 10784616
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages.
    Yang YF, Zou JP, Mu J, Wijesuriya R, Ono S, Walunas T, Bluestone J, Fujiwara H, Hamaoka T.
    Cancer Res; 1997 Sep 15; 57(18):4036-41. PubMed ID: 9307290
    [Abstract] [Full Text] [Related]

  • 15. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS, Kudelka AP, Kavanagh JJ, Verschraegen C, Edwards CL, Nash M, Levy L, Atkinson EN, Zhang HZ, Melichar B, Patenia R, Templin S, Scott W, Platsoucas CD.
    Clin Cancer Res; 2000 Jun 15; 6(6):2268-78. PubMed ID: 10873077
    [Abstract] [Full Text] [Related]

  • 16. Administration of IL-12 induces a CD3+ CD4- CD8- B220+ lymphoid population capable of eliciting cytolysis against Fas-positive tumor cells.
    Tsutsui T, Mu J, Ogawa M, Yu WG, Suda T, Nagaga S, Saji F, Murata Y, Fujiwara H, Hamaoka T.
    J Immunol; 1997 Sep 15; 159(6):2599-605. PubMed ID: 9300678
    [Abstract] [Full Text] [Related]

  • 17. Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity.
    Guo J, Wang B, Zhang M, Chen T, Yu Y, Regulier E, Homann HE, Qin Z, Ju DW, Cao X.
    Gene Ther; 2002 Jun 15; 9(12):793-803. PubMed ID: 12040461
    [Abstract] [Full Text] [Related]

  • 18. Generation of a tumor-specific systemic response after intratumoral injection of IL-12 and IL-18-loaded polylactic acid microspheres.
    Sabel MS, Arora A, Su G, Griffith KA, Mathiowitz E, Reineke JJ, Chang AE.
    J Immunother; 2007 Jun 15; 30(8):808-16. PubMed ID: 18049332
    [Abstract] [Full Text] [Related]

  • 19. Interleukin-12 activates NK cells for IFN-gamma-dependent and NKT cells for IFN-gamma-independent antimetastatic activity.
    Hafner M, Falk W, Echtenacher B, Männel DN.
    Eur Cytokine Netw; 1999 Dec 15; 10(4):541-8. PubMed ID: 10586121
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.